Armistice Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Armistice Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-500,000	Closed	-$57.2M	–	132
2020 Q3	$57.2M	Hold	500,000	–	–	2.08%	10
2020 Q2	$56.1M	Buy	500,000 +72,000	+17%	+$7.64M	2.46%	7
2020 Q1	$38.4M	Buy	428,000 +360,000	+529%	+$35.3M	2.38%	10
2019 Q4	$7.35M	Buy	+68,000	New	+$7.27M	0.42%	60
2019 Q1	–	Sell	-124,000	Closed	-$12.1M	–	95
2018 Q4	$12.1M	Buy	+124,000	New	+$14.7M	0.92%	26
2018 Q3	–	Sell	-112,000	Closed	-$13.9M	–	95
2018 Q2	$13.9M	Buy	+112,000	New	+$13.1M	0.91%	35
2017 Q3	–	Sell	-100,000	Closed	-$12.2M	–	79
2017 Q2	$12.2M	Sell	100,000 -6,000	-6%	-$698K	1.55%	22
2017 Q1	$12.9M	Buy	+106,000	New	+$13.7M	2.65%	14

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Armistice Capital's ALXN Position: Q4 2020 in Review

Armistice Capital sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 500,000 shares — an estimated $57.2M sold.

Armistice Capital first reported a position in ALXN in Q1 2017 and held it in 8 quarters. The position peaked at $57.2M in Q3 2020. 824 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Armistice Capital reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Armistice Capital sold 500,000 Alexion Pharmaceuticals shares in Q4 2020, an estimated $57.2M.
Armistice Capital first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 8 quarters.
Armistice Capital's Alexion Pharmaceuticals position peaked at $57.2M in Q3 2020.
824 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Armistice Capital's 13F filing for Q4 2020, filed 16 Feb 2021.